4 completed, 2 recruiting, 2 terminated, 2 unknown. 5 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Chronic Hepatitis B Virus Infection: new trials by email Literature Review of Chronic Hepatitis B Virus Infection trials Research Report on Chronic Hepatitis B Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection HH-006 - Chronic Hepatitis B Virus Infection | Phase 2 | Recruiting | Huahui Health | 45 | 2026-05-14 | 2026-06-15 |
| A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B IB-001, Placebo, Peginterferon Alfa-2A - Chronic Hepatitis B Virus Infection | Phase 1 | Recruiting | IntegerBio | 88 | 2026-02-20 | 2026-09-28 |
| A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients HH-006, 0.9% normal saline - Chronic Hepatitis B Virus Infection | Phase 1 | Completed | Huahui Health | 36 | 2024-12-20 | 2026-04-07 |
| A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen - Chronic Hepatitis B Virus Infection, Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 283 | 2024-11-11 | 2026-07-07 |
| A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection 162, Placebo - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Yangshengtang Co., Ltd | 1 | 2024-06-03 | 2024-07-16 |
| Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients PEG-IFNα, BRII-835 - Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 86 | 2023-08-22 | 2026-10-20 |
| Antiviral Therapy for Patients With Chronic Hepatitis B Infection Entecavir, Entecavir combined with Tenofovir Amibufenamide - Chronic Hepatitis B Virus Infection | Phase 2 | Unknown | Sun Yat-sen University | 238 | 2022-05-10 | 2022-05-19 |
| Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection Peginterferon Alfacon-2, Peginterferon Alfacon-2 placebo - Chronic Hepatitis B Virus Infection | Phase 3 | Completed | Beijing Kawin Technology Share-Holding Co., Ltd. | 336 | 2021-12-28 | 2024-08-09 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. EDP-721, Placebo (Part 1), EDP-721 (Part 2) - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Enanta Pharmaceuticals, Inc | 26 | 2021-08-02 | 2022-02-14 |
| Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy Ropeginterferon alfa-2b, Entecavir - Chronic Hepatitis B Virus Infection | Not applicable | Unknown | National Taiwan University Hospital | 90 | 2021-05-04 | 2022-12-27 |
| Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction BMS-914143 (Peginterferon Lambda-1a) - Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection | Phase 1 | Completed | Bristol-Myers Squibb | 43 | 2012-09-01 | 2013-06-05 |
Hepatitis B, Chronic (11) · Hepatitis B (4)
Blood-Borne Infections (11) · Chronic Disease (11) · Communicable Diseases (11) · DNA Virus Infections (11) · Digestive System Diseases (11) · Disease Attributes (11) · Hepadnaviridae Infections (11) · Hepatitis (11) · Hepatitis, Chronic (11) · Hepatitis, Viral, Human (11) · Infections (11) · Liver Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Virus Diseases (11)
entecavir (2) · Saline Solution (1) · peginterferon alfa-2a (1) · peginterferon lambda-1a (1)
Huahui Health (2) · Beijing Kawin Technology Share-Holding Co., Ltd. (1) · Brii Biosciences Limited (1) · Bristol-Myers Squibb (1) · Enanta Pharmaceuticals, Inc (1) · GlaxoSmithKline (1) · IntegerBio (1) · National Taiwan University Hospital (1) · Sun Yat-sen University (1) · Yangshengtang Co., Ltd (1)
China (6) · Australia (3) · New Zealand (3) · Hong Kong (2) · Singapore (2) · South Korea (2) · Taiwan (2) · United States (2) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1)
Chun-Jen Liu (1) · Edward Gane, MBChB, MD, FRACP, MNZ (1)